MD PhD FEBO 

 

 

Bahram Bodaghi, MD, PHD, FEBO is Professor of Ophthalmology & Visual Sciences at Sorbonne University in Paris, France. He coordinates the Teaching Hospital Department of Vision and Handicaps (View Maintain) and serves as Vice President of the French Society of Ophthalmology. He chairs the national University Council of Ophthalmology since 2013 and is actively involved in undergraduate and postgraduate teaching programs at the University of Paris. He has been elected President of the International Ocular Inflammation Society since 2015. Dr Bodaghi was trained as a resident at the University of Rene Descartes, in Paris. At the end of his residency, he started his experience in basic research in the Viral Immunology Unit, at the Pasteur Institute. During his PhD training, he focused on the pathophysiology of viral infections, especially CMV retinitis and reported on chemokine sequestration by viral chemoreceptors as a novel viral escape strategy. He performed medical uveitis fellowship at the Pitié-Salpêtrière Hospital in Paris. B. Bodaghi is a member of numerous national and international organizations. He served as Secretary General of the European Association for Vision and Eye Research (EVER) from 2008-12 and member ofthe ARVO annual program committee (2013-15). He was an International Board member of the BCSC (Intraocular Inflammation and Uveitis section) for the American Academy of Ophthalmology from 2005-11. Dr Bodaghi has published more than 220 papers in peer-reviewed journals and 25 textbook chapters. He serves on the editorial boards of several prestigious journals and is a member of major vision research and clinical ophthalmology societies. He has given more than 130 invited lectures around the world and organized the 2014 International Conference on Behçet’s Disease in Paris. Dr Bodaghi was the first ophthalmologist to win the Oudin Award of the French Society of Immunology. He also obtained the Senior Achievement award of the American Academy of Ophthalmology and the International Uveitis Study Group Prize. During the last decade, he mainly focused his efforts in the understanding of infectious agents associated with different forms of intraocular inflammation but also new therapeutic strategies in autoimmune uveitis. Dr Bodaghi’s team has developed a new model of experimental autoimmune uveitis in mice and showed the efficacy of intravitrealy injected regulatory T-cells as an anti-inflammatory cell therapy. This strategy has been approved for a clinical trial by regulatory agencies and will be proposed to patients with severe uveitis in order to analyze safety, tolerance and efficacy.